NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Texas on behalf of investors who purchased Agile Therapeutics, Inc. (NASDAQ:AGRX) securities between March 9, 2016 and January 3, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/agile-therapeutics-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Agile Therapeutics made materially false and/or misleading statements and/or failed to disclose that: (a) the Twirla contraceptive patch had an efficacy rating that fell below peer group standards; (b) over half of patients in its “Secure” Phase 3 Study discontinued the study early; and (c) the Twirla patch therefore allegedly had a slight chance of gaining approval by the U.S. Food and Drug Administration.
On January 3, 2017, Agile Therapeutics reported “positive top-line results” for the study, yet reported an efficacy measure that failed to meet the standard set by other approved contraceptive patches. In addition, more than 51% of subjects opted to discontinue the study. Upon this news, shares of Agile Therapeutics fell from a close of $5.70 per share on December 30, 2016, to a close of $2.63 per share on January 4, 2017.
If you suffered a loss in Agile Therapeutics you have until March 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email firstname.lastname@example.org, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/agile-therapeutics-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.